Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Deferred Revenue: 2016-2024

  • Ascendis Pharma A's Current Deferred Revenue fell 21.49% to $1.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.0 million, marking a year-over-year decrease of 21.49%. This contributed to the annual value of $1.0 million for FY2024, which is 20.48% down from last year.
  • As of Q4 2024, Ascendis Pharma A's Current Deferred Revenue stood at $1.0 million, which was down 21.49% from $1.3 million recorded in Q4 2023.
  • In the past 5 years, Ascendis Pharma A's Current Deferred Revenue registered a high of $3.0 million during Q4 2021, and its lowest value of $432,801 during Q4 2020.
  • In the last 2 years, Ascendis Pharma A's Current Deferred Revenue had a median value of $1.1 million in 2023 and averaged $1.1 million.
  • In the last 5 years, Ascendis Pharma A's Current Deferred Revenue plummeted by 54.43% in 2020 and then spiked by 587.49% in 2021.
  • Quarterly analysis of 4 years shows Ascendis Pharma A's Current Deferred Revenue stood at $432,801 in 2020, then surged by 587.49% to $3.0 million in 2021, then reached $1.3 million in 2023, then fell by 21.49% to $1.0 million in 2024.
  • Its Current Deferred Revenue stands at $1.0 million for Q4 2024, versus $1.3 million for Q4 2023 and $3.0 million for Q4 2021.